PETER S. KIM - 22 Mar 2024 Form 4 Insider Report for Entrada Therapeutics, Inc. (TRDA)

Role
Director
Signature
/s/ Jared Cohen, as Attorney-in-Fact
Issuer symbol
TRDA
Transactions as of
22 Mar 2024
Net transactions value
+$122,882
Form type
4
Filing time
26 Mar 2024, 17:57:20 UTC
Previous filing
21 Mar 2024
Next filing
01 Apr 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TRDA Common Stock Purchase $42,901 +3,118 +6.3% $13.76 52,894 22 Mar 2024 Direct F1
transaction TRDA Common Stock Purchase $42,472 +3,180 +6% $13.36 56,074 25 Mar 2024 Direct F2
transaction TRDA Common Stock Purchase $37,509 +2,750 +4.9% $13.64 58,824 26 Mar 2024 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.68 to $13.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F2 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.22 to $13.54, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $13.62 to $13.65, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.